Targeting DNA methylation for treating triple-negative breast cancer

Triple-negative breast cancer (TNBC) accounts for 15–20% of all invasive breast cancers and tends to have aggressive histological features and poor clinical outcomes. Unlike, estrogen receptor- or HER2-positive diseases, TNBC patients currently lack the US FDA-approved targeted therapies. DNA methyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jia, Zayas, Jacqueline, Qin, Bo, Wang, Liewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2019
Materias:
Special Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026764/
https://www.ncbi.nlm.nih.gov/pubmed/31755366
http://dx.doi.org/10.2217/pgs-2019-0078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026764/
https://www.ncbi.nlm.nih.gov/pubmed/31755366
http://dx.doi.org/10.2217/pgs-2019-0078

Ejemplares similares